drugset / Trial / NCT02640820

Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)

NCT02640820 ↗

Phase 2 Unknown 83 enrolled RXi Pharmaceuticals, Corp.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Warts are benign epidermal tumors caused by human papillomaviruses (HPVs). The active pharmaceutical ingredient DPCP has been used for many years as a compounded formulation in acetone for the treatment of warts, alopecia areata and more recently, cutaneous metastatic melanoma lesions. An improved topical ointment formulation of DPCP called Samcyprone™ will be evaluated for the treatment of common warts.

Timeline

Start
2015-12
Primary completion
2018-01
Completion
2018-05

Drugs

EvaluationDrugModalityDoseRoute
Subject DPCP Unknown — Topical